EN CN

CAN008

China IND

Taiwan Phase 1

CAN008 is an antibody-like CD95 receptor/Fc-fusion protein which blocks the CD95 ligand from binding to CD95, reducing cancer-cell migration in malignant glioma and protecting tumor-infiltrating immune cells from apoptosis. Indicated for glioblastoma, CAN008 has shown outstanding survival benefit for CD95L positive GBM patients in the completed Phase II study in EU. 


CANbridge has the exclusive license for development, manufacture and commercialization of CAN008 for the territories of Greater China (include Hong Kong, Macau and Taiwan).


Indication:Glioblastoma


Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are non-specific. hey may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Worsening of symptoms often is rapid. This may progress to unconsciousness.


The cause of most cases is unclear. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li–Fraumeni syndrome and, previous radiation therapy. Glioblastomas represent 15% of brain tumors. They can either start from normal brain cells or develop from an existing low-grade astrocytoma. The diagnosis typically is made by a combination of CT scan, MRI scan, and tissue biopsy.


There is no clear way to prevent the disease. Typically, treatment involves surgery, after which chemotherapy and radiation therapy are used. The medication temozolomide is used frequently as part of chemotherapy. High dose steroids may be used to help reduce swelling and decrease symptoms. It is unclear whether trying to remove all or simply most of the cancer, is better.


Despite maximum treatment, the cancer usually recurs. The most common length of survival following diagnosis is 12 to 15 months, with fewer than 3% to 5% of people surviving longer than five years. Without treatment, survival is typically three months. It is the most common cancer that begins within the brain and the second most common brain tumor, after meningioma. About 3 per 100,000 people develop the disease a year. It most often begins around 64 years of age and occurs more commonly in males than females. Immunotherapy is being studied in glioblastoma with promising results.